These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 38232092)

  • 1. Serum biomarkers of inflammation and vascular damage upon SARS-Cov-2 mRNA vaccine in patients with thymic epithelial tumors.
    Cernera G; Gelzo M; De Placido P; Pietroluongo E; Raia M; Scalia G; Tortora M; Formisano P; Palmieri G; Giuliano M; Castaldo G
    Clin Chem Lab Med; 2024 May; 62(6):1198-1205. PubMed ID: 38232092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunocytometric analysis of patients with thymic epithelial tumors revealed that COVID-19 vaccine booster strongly enhanced the immune response.
    Cernera G; Gelzo M; De Placido P; Ottaviano M; Pietroluongo E; Raia M; Scalia G; Tortora M; Castaldo G; Formisano P; Palmieri G; Giuliano M
    Front Immunol; 2023; 14():1233056. PubMed ID: 37705978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SARS-CoV-2 vaccine in patients with thymic epithelial tumours with and without active or pre-existing autoimmune disorders: Brief report of a TYME network safety analysis.
    Giugliano F; Zucali PA; Galli G; Ballatore Z; Corti C; Aliaga PT; Uliano J; Vivanet G; Curigliano G; Conforti F; Queirolo P; Berardi R; Manglaviti S; Apollonio G; Perrino M; Borea F; D'Antonio F; Garassino MC; De Pas T
    Eur J Cancer; 2022 May; 166():202-207. PubMed ID: 35306318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impaired Seroconversion After Severe Acute Respiratory Syndrome Coronavirus 2 mRNA Vaccine in Patients With Thymic Epithelial Tumors.
    Pietroluongo E; De Placido P; Tortora M; Martinelli C; Viggiano A; Saponaro MR; Caltavituro A; Buonaiuto R; Morra R; Ottaviano M; Del Deo V; Cernera G; Gelzo M; Malfitano AM; Di Tolla MF; De Angelis C; Arpino G; Terracciano D; Bianco R; Veneziani BM; Formisano P; Castaldo G; Palmieri G; De Placido S; Giuliano M
    J Thorac Oncol; 2023 Oct; 18(10):1399-1407. PubMed ID: 37390981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
    Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
    Front Immunol; 2022; 13():863554. PubMed ID: 35711445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inflammation and Platelet Activation After COVID-19 Vaccines - Possible Mechanisms Behind Vaccine-Induced Immune Thrombocytopenia and Thrombosis.
    Ostrowski SR; Søgaard OS; Tolstrup M; Stærke NB; Lundgren J; Østergaard L; Hvas AM
    Front Immunol; 2021; 12():779453. PubMed ID: 34887867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and safety after the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors on active treatment: a prospective cohort study.
    Lasagna A; Bergami F; Lilleri D; Percivalle E; Quaccini M; Alessio N; Comolli G; Sarasini A; Sammartino JC; Ferrari A; Arena F; Secondino S; Cicognini D; Schiavo R; Lo Cascio G; Cavanna L; Baldanti F; Pedrazzoli P; Cassaniti I
    ESMO Open; 2022 Apr; 7(2):100458. PubMed ID: 35427842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial.
    Oda Y; Kumagai Y; Kanai M; Iwama Y; Okura I; Minamida T; Yagi Y; Kurosawa T; Greener B; Zhang Y; Walson JL
    Lancet Infect Dis; 2024 Apr; 24(4):351-360. PubMed ID: 38141632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of myocarditis and pericarditis after a COVID-19 mRNA vaccine booster and after COVID-19 in those with and without prior SARS-CoV-2 infection: A self-controlled case series analysis in England.
    Stowe J; Miller E; Andrews N; Whitaker HJ
    PLoS Med; 2023 Jun; 20(6):e1004245. PubMed ID: 37285378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serological findings following the second and third SARS-CoV-2 vaccines in lung transplant recipients.
    Bárczi E; Varga V; Nagy A; Eszes N; Jáky-Kováts Z; Müller V; Bohács A
    Immun Inflamm Dis; 2022 Aug; 10(8):e646. PubMed ID: 35894705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of Second Allergic Reaction to SARS-CoV-2 Vaccines: A Systematic Review and Meta-analysis.
    Chu DK; Abrams EM; Golden DBK; Blumenthal KG; Wolfson AR; Stone CA; Krantz MS; Shaker M; Greenhawt M
    JAMA Intern Med; 2022 Apr; 182(4):376-385. PubMed ID: 35188528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SARS-CoV-2 infection in cancer patients on active therapy after the booster dose of mRNA vaccines.
    Di Giacomo AM; Giacobini G; Anichini G; Gandolfo C; D'alonzo V; Calabrò L; Lofiego MF; Cusi MG; Maio M
    Eur J Cancer; 2022 Aug; 171():143-149. PubMed ID: 35717822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. mRNA vaccine-induced T cells respond identically to SARS-CoV-2 variants of concern but differ in longevity and homing properties depending on prior infection status.
    Neidleman J; Luo X; McGregor M; Xie G; Murray V; Greene WC; Lee SA; Roan NR
    Elife; 2021 Oct; 10():. PubMed ID: 34636722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Study of efficacy and longevity of immune response to third and fourth doses of COVID-19 vaccines in patients with cancer: A single arm clinical trial.
    Thakkar A; Pradhan K; Duva B; Carreno JM; Sahu S; Thiruthuvanathan V; Campbell S; Gallego S; Bhagat TD; Rivera J; Choudhary G; Olea R; Sabalza M; Shapiro LC; Lee M; Quinn R; Mantzaris I; Chu E; Will B; Pirofski LA; Krammer F; Verma A; Halmos B
    Elife; 2023 Mar; 12():. PubMed ID: 36975207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A whole blood test to measure SARS-CoV-2-specific response in COVID-19 patients.
    Petrone L; Petruccioli E; Vanini V; Cuzzi G; Najafi Fard S; Alonzi T; Castilletti C; Palmieri F; Gualano G; Vittozzi P; Nicastri E; Lepore L; Antinori A; Vergori A; Caccamo N; Cantini F; Girardi E; Ippolito G; Grifoni A; Goletti D
    Clin Microbiol Infect; 2021 Feb; 27(2):286.e7-286.e13. PubMed ID: 33045370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploratory analysis to identify the best antigen and the best immune biomarkers to study SARS-CoV-2 infection.
    Petruccioli E; Najafi Fard S; Navarra A; Petrone L; Vanini V; Cuzzi G; Gualano G; Pierelli L; Bertoletti A; Nicastri E; Palmieri F; Ippolito G; Goletti D
    J Transl Med; 2021 Jun; 19(1):272. PubMed ID: 34174875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore.
    Ng OT; Marimuthu K; Lim N; Lim ZQ; Thevasagayam NM; Koh V; Chiew CJ; Ma S; Koh M; Low PY; Tan SB; Ho J; Maurer-Stroh S; Lee VJM; Leo YS; Tan KB; Cook AR; Tan CC
    JAMA Netw Open; 2022 Aug; 5(8):e2228900. PubMed ID: 36018588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic and T cell-associated responses to SARS-CoV-2 immunisation in gut inflammation (STAR SIGN study): effects of biologics on vaccination efficacy of the third dose of mRNA vaccines against SARS-CoV-2.
    Woelfel S; Dütschler J; König M; Graf N; Oikonomou V; Krieger C; Truniger S; Franke A; Eckhold A; Forsch K; Wyss J; Krupka N; Albrich W; Frei N; Geissler N; Schaub P; ; Friedrich M; Misselwitz B; Korte W; Bürgi JJ; Brand S
    Aliment Pharmacol Ther; 2023 Jan; 57(1):103-116. PubMed ID: 36307899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of Myocarditis After Sequential Doses of COVID-19 Vaccine and SARS-CoV-2 Infection by Age and Sex.
    Patone M; Mei XW; Handunnetthi L; Dixon S; Zaccardi F; Shankar-Hari M; Watkinson P; Khunti K; Harnden A; Coupland CAC; Channon KM; Mills NL; Sheikh A; Hippisley-Cox J
    Circulation; 2022 Sep; 146(10):743-754. PubMed ID: 35993236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.